News and Trends 13 Jan 2017 RNA Spray fights Viruses and could Sidestep problems with GMOs RNA and clay could be the future of crop protection and manipulation of plants’ traits. Researchers have managed to use these ingredients to create a spray capable of “vaccinating” plants, teaching them to recognize the genetic material of viruses. RNA-based therapies may have suffered a recent blow in the clinic this week, but when it comes […] January 13, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2017 Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities Researchers from the UK have described a new treatment for cavities that could get rid of fillings and cements by employing an Alzheimer’s drug. Most of us have visited the dentist to fill a cavity. The usual procedure involves removing the damaged area and replacing it with mineral materials. But what if you could let […] January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Jan 2017 Bacon Jewelry and Tissue Engineered Bio Fashion from the Future Biodesigner Amy Congdon envisions a future where biotechnology is essential in all aspects of our lives, from regenerating organs to fashion. Amy Congdon is a designer based in London that uses her art to explore the implications of biotech. In particular, most of her work revolves around the intersection of two fields that might seem utterly unrelated: […] January 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2017 ‘Packaged’ CRISPR Systems to Standardize novel Biomedical Research There’s a growing appetite to refine and standardize CRISPR protocols, as its application expands into different areas of genomic research. The Wellcome Trust and Desktop Genomics have recent advances to make it more efficient and controllable. Outside of the high-stakes world of therapeutic CRISPR, which has enjoyed gambling-like investment and whose legal future is unfolding in court, this […] January 6, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 5 Jan 2017 Investors Jump on Hypersensitivity Peptides from GSK Spinout Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion, Fountain Healthcare Partners, Advent Life Sciences, Novo A/S, and Orbimed. NeRRe Therapeutics, a UK-based spinout of GSK, nailed down a €27M (£23M) Series B round. Helmed by […] January 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 This British Biotech is buying its way into the Crowded NASH Space Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2016 BMS Offers €850M for a British Oncolytic Virus better than CAR-T BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […] December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2016 Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […] December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success. December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number […] December 12, 2016 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 UPDATE: More Good News on a Cannabis Derivative for Epilepsy Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published on 27/09/2016 GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of […] December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2016 Video: Chatting with Immunocore about the Potential of Immuno-oncology At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe’s hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest biotech successes in Europe: the company raised the largest round ever on the continent (€300M!), built a solid technological platform and recruited top talents to manage […] December 5, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […] December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email